PCI Synthesis, a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, is changing its name to SEQENS.  The name change comes six months after PCI Synthesis was acquired by Novacap. The new corporate entity, SEQENs, also combines PCAS, Uetikon and Proteus.  The move positions SEQENS as an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering outstanding perfo...